Webinar On Managing the FDA form "483": Inspection Observations

Event Details

Time: May 12, 2015 from 1pm to 2pm
Location: Canada
Street: 5939 Candlebrook Court
City/Town: Mississauga, ON
Website or Map: https://compliancetrainings.c…
Phone: 4169154458
Event Type: webinar
Organized By: Compliance Trainings
Latest Activity: Apr 16, 2015

Export to Outlook or iCal (.ics)

0 members like this

Event Description

Description :

This webinar is a complete guide on how to manage the FDA's 483 observations during and after an inspection. How you respond can make or break you.

Form FDA 483 is a list of observations made by FDA during an inspection. Observations are not a good thing. At the conclusion of an inspection, the FDA investigator lists specific examples that demonstrate an apparent violation of the applicable FDA regulations. You and the FDA investigator will discuss what the investigator found. At that point you are put on notice about your problems. You are warned that if you fail to correct the problems, it may result in further action by the FDA, such as levying civil money penalties, seizure, injunction, and/or prosecution. Firms are well advised to take the written 483 observations and FDA’s verbal warning seriously. A failure to promptly respond in writing to the FDA makes the situation even worse. As an immediate business consequence, marketing departments should expect competitors to show customers your 483. Your 483 is used against you as a bad report.

Prior to an inspection, the FDA investigator reviews your prior 483s and checks to make sure you corrected your previous problems. You will be held accountable for your prior response. What you promised to correct and what you did not correct becomes a critical factor in how FDA classifies your firm. What you fail to correct may lay for the foundation for long-term serious consequences with FDA. Your firm’s management is held accountable for its failure to adequately correct its regulatory problems. In some cases, the FDA will hold senior executive management personally liable for their managerial actions or inaction. Again, what a firm promises and what a firm does in response to a 483 makes a real difference.

Areas Covered in the Session :

What the Form FDA “483” means

How to manage the FDA’s 483 observations during and after an inspection

What the FDA considers important

How to respond effectively to 483 observations

Planning for other problems

Learn how to manage your regulatory profile with the FDA

Who Will Benefit:

Regulatory Affairs Professionals

In-house Legal Counsel

Senior Managers for Manufacturing and Quality Assurance

FDA consultants